MASLD has become the most common chronic liver disease worldwide. The authors review the features of the disease as well as ...

To prevent the spread of inaccurate information, academic and health care institutions will need to equip scientists and clinicians to engage effectively on nontraditional media platforms.

This Double Take video explores the link between certain strains of human papillomavirus and cancer and reviews the evidence ...

The need to suppress a patient’s immune system after the transplantation of allogeneic cells is associated with wide-ranging side effects. We report the outcomes of transplantation of ...

Although xenon may have neuroprotective effects, there is no strong evidence that it aids in short-term, high-altitude performance. Success is more likely a result of acclimatization, oxygen suppor ...

Understanding today’s corporatization of U.S. health care requires seeing it from a historical perspective, as a process that began with a change in the business model of care delivery in the 1920s.

“Corporatization” of health care, a process predicted decades ago, now refers to the general trend throughout the industry toward higher levels of integrated control by consolidated profit-seeking ...

The rising tide of chronic kidney disease among patients with type 2 diabetes continues to challenge clinicians and health systems worldwide.1 Advances have been made in the management of chronic k ...

Children were recently discovered to have been exposed to high levels of lead in Milwaukee schools — the latest episode in an ongoing toxic pandemic. This time, no help was forthcoming from the CDC.

A 71-year-old woman with systemic lupus erythematosus presented to the ophthalmology clinic for an annual screening examination for hydroxychloroquine-related toxic effects. She reported no vision ...

Audio Interview from the New England Journal of Medicine — Interview with Nancy Tomes on the century-long transition to a corporate business model in U.S. health care.

How much is enough in the treatment of newly diagnosed multiple myeloma? As clinicians, we want to provide efficacious treatments for our patients to avoid undertreating them. However, we also want ...